Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.06.19.733483

A complete RXFP1-relaxin interaction model unlocks the design of potent mini-protein modulators

Abstract

Relaxin family peptide receptor 1 (RXFP1) is a multi-domain GPCR with compelling therapeutic potential, yet uncertainty surrounding the mechanism of its activation by the hormone H2 relaxin has hindered the development of selective modulators. Here, we combine deep learning based structural modelling with de novo protein design to overcome this barrier. We generate a high-confidence structural model of the RXFP1-relaxin complex that is strongly supported by existing biochemical and functional evidence. This model reveals that relaxin engagement stabilises the RXFP1 extracellular linker, thereby triggering receptor activation. Guided by this model, we design mini-protein modulators that either block linker stabilisation or enforce it and induce an active receptor geometry. These molecules act as potent, selective RXFP1 antagonists or agonists, achieving low-nanomolar activity in both engineered and endogenously expressing cell lines despite adopting folds unrelated to relaxin. Together, these findings define the mechanistic basis of RXFP1 signalling, establish the first de novo agonists and antagonists of this receptor, and demonstrate how AI-enabled modelling and design can target structurally complex GPCRs previously inaccessible to structure-guided drug discovery.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Clement, J., Lkhagvajargal, T., Hoare, B. L., Myint, T., Fox, D. R., Wang, C., Knott, G. J., Bathgate, R. A., Grinter, R.. 2026-06-22. A complete RXFP1-relaxin interaction model unlocks the design of potent mini-protein modulators. https://doi.org/10.64898/2026.06.19.733483

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Structural basis of SBDS dysfunction in Shwachman-Diamond Syndrome

Surveillance of functional centers in the mature 60S ribosomal subunit by SBDS licenses its translational debut. Timely release of eIF6 from 60S by SBDS is essential to permit 40S joining. Biallelic mutations in SBDS associated with Shwachman-Diamond syndrome (SDS), an inherited ribosomopathy, impair dissociation of eIF6 from 60S. How SBDS variants that bind to 60S structurally perturb the maturation and surveillance of 60S is yet to be deciphered. Here, we report high-resolution cryogenic electron microscopy (cryo-EM) structures of human SBDS and pathogenic variants in complex with human 60S. The structures reveal that disease mutations disrupt key interactions of SBDS with the functional centers of the 60S subunit destabilizing critical bases and protein interactions across the P-site, peptidyl transferase center, polypeptide exit tunnel and GTPase-associated center. These mutations remodel the N-terminal contacts with 60S, altering critical interactions with uL16 (RPL10) distant from the mutation site. Mutations in domains II and III trigger conformational changes that propagate across the entirety of SBDS and remodel distant ribosomal regions, revealing an elegant mechanism of pathogenic allostery. The profound effects of SBDS mutations on both the surveillance and mature conformation of the 60S subunit provide a structural framework for understanding the molecular pathology of SDS.

biochemistry↗

Deep sequence-function mapping reveals computationally unpredictable epistatic trajectories that drive laboratory evolution

The black-box nature of directed evolution has been constraining advances in enzyme engineering and the wider application of engineered biocatalysts. While conventional deep sequence-function mapping has delivered insights into sequence space architecture, it lacks the ability to analyse adaptive landscapes and fully grasp the long-term impact of epistasis on the accessibility of evolutionary trajectories. Here, we introduce Deep Evolutionary Trajectory Mapping (dETM) which tracks the winners of a multi-round evolutionary campaign to map catalytic rates across the adaptive landscape of an imine reductase. We identified founder variants as stepping stones towards fitness peaks and recognise positive epistasis as their competitive advantage over alternative lineages. State-of-the-art machine learning models could not predict the resulting winning trajectories, which highlights the importance of decoding design principles for successful evolution experimentally. Permissive selection and ultrahigh-throughput screening emerge as foundations of derisking landscape traversal by keeping multiple paths accessible and avoiding diminishing returns.

biochemistry↗

De novo design of antiviral monobody binders

Monobodies (Mobs) are a class of immunoglobulin (Ig)-like proteins that have emerged as promising therapeutic scaffolds for applications ranging from antiviral therapy to cancer treatment. Unlike conventional monoclonal antibodies (mAbs), Mobs can be readily expressed in Escherichia coli at high yields, offering important advantages in overall developability. However, discovering antigen-specific Mobs with high binding affinity traditionally requires screening large, randomized in vitro libraries. To optimize Mob discovery, we developed MobGen, a computational pipeline for de novo design of Mob binders against viral antigens. As a proof of concept, we generated Mobs that bind the SARS-CoV-2 Spike glycoprotein Receptor Binding Domain (RBD). Subsequent in silico optimization improved production yield, thermal and conformational stability, binding affinity, and antiviral activity, demonstrating a promising approach for rapidly developing antibody-like molecules that target viral entry. These findings highlight MobGen's potential for de novo design of Mobs against emerging viruses with pandemic potential.

biochemistry↗